Drug Profile

OV 4071

Alternative Names: OV-4071

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ovid Therapeutics
Class Antipsychotics
Mechanism of Action K Cl-cotransporter agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Psychotic disorders

Most Recent Events

25 Mar 2025 Pharmacodynamic, adverse events and pharmacokinetic data from a preclinical studies in Psychotic disorders released by Ovid therapeutics
25 Mar 2025 Ovid Therapeutics plans to initiate phase Ib trial in third quarter of 2026
24 Mar 2025 Preclinical trials in Psychotic disorders in USA (IM)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com